Public comment period · §3
Draft monograph: orforglipron — disposition
The disposition of every submission and the amendments that resulted.
§3Disposition and amendments
§3.1Disposition table
Table 1. Every submission with its disposition. Each row links to the submission in full.
| Reference | Respondent | Point raised | Disposition |
|---|---|---|---|
| DRAFT-ORFORGLIPRON/001 | Dr Yusuf Whitmarsh-Obi | Open-label extension data are presented alongside randomised data without distinction | Accepted |
| DRAFT-ORFORGLIPRON/002 | Dr Leonhard Quenneville | The mechanism section is written with more confidence than the clinical section it precedes | Accepted in part |
| DRAFT-ORFORGLIPRON/003 | Dr Anselm Thorsby-Nakamura | Quantitative claims are reproduced without the method that produced them | Accepted |
| DRAFT-ORFORGLIPRON/004 | Dr Lorcan Zaleski-Mbeki | The absence of a rare harm in the trial set is presented as reassurance | Accepted |
| DRAFT-ORFORGLIPRON/005 | Dr Piotr Hollingworth | The pharmacokinetic section does not connect half-life to the dosing schedule | Accepted |
| DRAFT-ORFORGLIPRON/006 | Dr Dmitri Nordhagen | What happens when the compound is stopped is not addressed | Accepted |
| DRAFT-ORFORGLIPRON/007 | Dr Jolyon Grünbaum-Sowande | A near-isobaric analogue is not distinguished by the identity determination described | Accepted |
| DRAFT-ORFORGLIPRON/008 | Dr Vasilisa Sandringham-Adu | The population to which the headline estimate applies is not stated with the estimate | Accepted |
| DRAFT-ORFORGLIPRON/009 | Dr Fenella Lavrentiev | What happens to weight after the compound is stopped is not in the assessed outcomes | Accepted |
| DRAFT-ORFORGLIPRON/010 | Dr Wolfram Kaltenbach-Mensah | Glycaemic trials and weight-management trials are drawn on interchangeably | Accepted |
| 10 submissions in total. | |||
§3.2Summary by disposition
Table 2. Counts by disposition, with the meaning of each.
| Disposition | Count | Meaning |
|---|---|---|
| Accepted | 9 | The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission. |
| Accepted in part | 1 | Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined. |
| Noted, no amendment | 0 | The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response. |
| Not accepted | 0 | The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it. |
§3.3Resulting amendments
- Open-label extension data are presented alongside randomised data without distinction — arising from DRAFT-ORFORGLIPRON/001. Extension data now appear in a separate table headed as uncontrolled follow-up, with a standing note on differential withdrawal.
- The mechanism section is written with more confidence than the clinical section it precedes — arising from DRAFT-ORFORGLIPRON/002. Every pharmacology section now closes with a statement identifying which described actions are supported by clinical evidence assessed in §3 and which are not. The pharmacology itself is stated as the sources state it.
- Quantitative claims are reproduced without the method that produced them — arising from DRAFT-ORFORGLIPRON/003. Every quantitative claim now carries the determination that produced it at the point of use, and figures obtained by non-comparable methods are no longer presented in the same row or sentence.
- The absence of a rare harm in the trial set is presented as reassurance — arising from DRAFT-ORFORGLIPRON/004. Wherever the monograph reports that an event was not observed, it now states the total exposure and the frequency the contributing trials could have detected, so that the absence is read as the limit of the evidence rather than as a finding.
- The pharmacokinetic section does not connect half-life to the dosing schedule — arising from DRAFT-ORFORGLIPRON/005. The pharmacokinetic section now states approximate time to steady state alongside the half-life and dosing interval, with the assumption of first-order elimination stated, and records where the assumption is not supported for this compound.
- What happens when the compound is stopped is not addressed — arising from DRAFT-ORFORGLIPRON/006. Discontinuation trajectory is now an assessed outcome in every monograph where a contributing trial measured it, and a recorded evidence gap in every monograph where none did, so that its absence is visible rather than silent.
- A near-isobaric analogue is not distinguished by the identity determination described — arising from DRAFT-ORFORGLIPRON/007. The analytical section now states the resolving power required to discriminate the pair, names the pair explicitly, and records that an identity claim made below that resolution is not conformant with the identity standard.
- The population to which the headline estimate applies is not stated with the estimate — arising from DRAFT-ORFORGLIPRON/008. Every headline estimate now carries a one-line statement of the population in which it was observed, and the full eligibility criteria are reported in the included-studies table rather than only in the source.
- What happens to weight after the compound is stopped is not in the assessed outcomes — arising from DRAFT-ORFORGLIPRON/009. Post-withdrawal trajectory is now an assessed outcome wherever a withdrawal period was studied, rated on the same scale as the others. Where no withdrawal period was studied the outcome is recorded as not assessed.
- Glycaemic trials and weight-management trials are drawn on interchangeably — arising from DRAFT-ORFORGLIPRON/010. Every effect estimate now names its programme, and the assessed-outcome table is split where a compound has more than one.
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-CP-030/3 · https://compoundevidence.com/comment-periods/draft-orforglipron-monograph/disposition/ · retrieved 30 July 2026